FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2018/03/012550 [Registered on: 13/03/2018] Trial Registered Retrospectively
Last Modified On: 07/03/2018
Post Graduate Thesis  Yes 
Type of Trial  Observational 
Type of Study   observational study 
Study Design  Other 
Public Title of Study   Unani medicine Habb-e-Sandroos for piles 
Scientific Title of Study   Efficacy of Habb-e-Sandroos in Bawaseer Ghaira (Internal Hemorrhoids) 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr mehjabeen fatimah 
Designation  lecturer  
Affiliation  national institute of unani medicine 
Address  national institute of unani medicine,

Bangalore
KARNATAKA
560091
India 
Phone  08057438462  
Fax    
Email  fatimahmehjabeen@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr mehjabeen fatimah 
Designation  lecturer  
Affiliation  national institute of unani medicine 
Address  national institute of unani medicine, bangalore-91

Bangalore
KARNATAKA
560091
India 
Phone  08057438462  
Fax    
Email  fatimahmehjabeen@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Mahfooz Alam 
Designation  P.G.Scholar 
Affiliation  national institute of unani medicine 
Address  national institute of unani medicine,
kottegipalya, bangalore-91
Bangalore
KARNATAKA
560091
India 
Phone  8050014042  
Fax    
Email  drmahznium@gmail.com  
 
Source of Monetary or Material Support  
Mational Institute of Unani medicine, kottigepalya, bangalore-91 
 
Primary Sponsor  
Name  National Institute of Unani medicine  
Address  kottigepalya, bangalore-91, karnataka 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Mahfooz Alam  National Institute of Unani Medicine And Hospital   Dept of Surgery, Room 54 (Operation Theatre)
Bangalore
KARNATAKA 
8050014042

drmahznium@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  suffering from bawaseer-e-Ghaira(internal hemorrhoids),  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Habb-e-Samdroos  Hab-e-Sandroos, 2 tablets each weighing 0.5g, thrice in a day for the duration of protocol. 
 
Inclusion Criteria  
Age From  20.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1.Diagnosed patients of Ist and IInd degree hemorrhoid confirmed by proctoscopy.

2.Patients of either sex.

3.Patients of 20-65 years of age.

4.Controlled Hypertensive Patients.
5.Controlled Diabetic Patients.
ï‚· Patients willing to participate in the study and ready to follow the protocol. 
 
ExclusionCriteria 
Details  1. III and IV degree internal hemorrhoids.

2. Patients with bleeding disorders.

3. Pregnant and lactating women.
4. Severe systemic illnesses. 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Not Applicable 
Blinding/Masking   Participant Blinded 
Primary Outcome  
Outcome  TimePoints 
amount of bleeding

regression of pile mass(grade-1, 2, 3, 4)

bleeding points
 
0 day,

15th day

30th day

45th day

After 1 month after protocol duration (after 1month by completing 45days)

After 2 months by completing protocol duration 
 
Secondary Outcome  
Outcome  TimePoints 
Mucus discharge (mild moderate severe
mild moderate severe)

Itching 
0 daay

15 day

30 day

45 day

1 month after completing protocol

2 months after completing protocol 
 
Target Sample Size   Total Sample Size="30"
Sample Size from India="30" 
Final Enrollment numbers achieved (Total)= "30"
Final Enrollment numbers achieved (India)="30" 
Phase of Trial   Phase 2 
Date of First Enrollment (India)   01/08/2015 
Date of Study Completion (India) 01/01/2017 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) 01/01/2017 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   not yet  
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  
this clinical study entitled “Efficacy of Habb-e-Sandroos in Bawaseer Ghaira (Internal Hemorrhoids)” was conducted at OPDs and IPDs of National Institute of Unani Medicine hospital, Bengaluru from August 2015 to January 2017. This was executed after the approval of study protocol by Institutional Ethical Committee NIUM, Bangaluru under IEC No: NIUM/IEC/2014-15/JAR/01. 
The studies showed that majority of the patients were in the range (21-40) years of age. The Mean age was found to be 36.90 with SD ± 9.86. They were predominantly males. In which 80% patients were married and 33.3 % among them were having familial history. Most of them were from labour class i.e lower middle class who were using less fibrous diet, increased use of non-veg and junk food. They were having unsatisfactory bowel,constipation, passing of hard stool, straining at stool and more stay-time in toilets were completely relieved. The subjective complaints of bleeding pre-rectum, mucus discharge, pruritus ani (itching), and prolapse of pile mass were completely relived at the end of protocol with significant p-value 0.001, 0.026, 0.003 and 0.001 respectively. In the objective parameters of bleeding during examination, 80% patients were having bleeding. They showed complete relived at the end of protocol i.e 100% with significance p-value 0.001. All patients had bleeding points which were disappeared at the end of 4th follow-up with significant p-value <0.001. Out of total 83 number of primary pile masses, 32 piles masses were of grade-I and 51 pile masses were of grade-II. In grade-I primary pile mass out of 32 pile masses, 31 pile masses were relieved at the end of protocol i.e 96.88%. Overall 22 patients got completely relieved. Whereas as in grade-II pile mass group, out of 51 pile mass 38 pile mass collectively were completely disappeared i.e 74.51% (38) at the end of protocol period with p-value 0.011 moderately significant. Out of this 38 pile masses, the number of piles relieved at different positions 3, 7 and 11 O`clock were 7, 16, and 15 respectively. Overall 16 patients i.e. 31.37% were got fully cured. No report of recurrence after the end of protocol. Among all the affected patients with sphincter spasm, 94.73% were got relief. It was found that majority of patients were from Damvi mizaj followed by Balghami and Safravi mizaj. Both Damvi and Balghami mizaj patients were common sufferers. They together constituted 80% of the affected patients. No patients of saudavi mizaj come under our study.

The study is not the final and complete evaluation of the test drug but an initiation to provide base for further studies on bleeding disorders, platelet count, PPT, wound healing, collagen formation rate and muscular flaccidity or toning.
 
Close